(Total Views: 197)
Posted On: 10/06/2020 3:21:09 PM
Post# of 36541
So that would be a winding road to overseas approval:
1) We need the IND approval from US FDA - required for the BK deal to move forward.
2) BK could start trials and even complete them, and the data could be fantastic. But that would be a temporary dead end, as they are requiring US FDA approval to seek approval from their own FDA.
3) NGIO would have to list common and/or preferred shares to generate capital for trials in the US.
4) US trials would need to complete and get approved.
5) Then BK could go for approvals overseas.
That's a long path...
1) We need the IND approval from US FDA - required for the BK deal to move forward.
2) BK could start trials and even complete them, and the data could be fantastic. But that would be a temporary dead end, as they are requiring US FDA approval to seek approval from their own FDA.
3) NGIO would have to list common and/or preferred shares to generate capital for trials in the US.
4) US trials would need to complete and get approved.
5) Then BK could go for approvals overseas.
That's a long path...
(0)
(0)Scroll down for more posts ▼
